FDA Approves Regeneron’s Pasatru for Ultra-Rare ‘Stone Man Disease’

The FDA has approved Pasatru (garetosmab-grts), a Regeneron antibody for fibrodysplasia ossificans progressiva (FOP) — an ultra-rare disorder often called “stone man disease,” in which muscles, tendons and ligaments progressively turn to bone.

What the disease does

FOP is vanishingly rare, with only about 900 people diagnosed worldwide. As abnormal bone — heterotopic ossification — accumulates, mobility is lost. Most patients are wheelchair-bound by age 30, and median survival is around 56.

The condition is unusually cruel in its mechanics. Soft tissue that should remain flexible ossifies into a second skeleton, progressively locking joints in whatever position they held when the bone formed. Patients lose the ability to raise their arms, then to turn their heads, then to open their mouths fully — each loss permanent, because the new bone does not resorb.

Trauma makes it worse. Injury, surgery and even intramuscular injections can trigger flare-ups that produce new bone, which means routine medical care carries risk and surgical removal of existing lesions typically provokes more ossification than it relieves.

How the drug works

Approved August 20, 2026, Pasatru is a monoclonal antibody blocking Activin A, a protein driving the bony lesions.

The mechanism reflects a genuinely elegant piece of disease biology. FOP is caused by a mutation in a receptor that normally responds to bone-forming signals. The mutation makes that receptor respond abnormally to Activin A — a protein that in healthy tissue does not drive bone formation at all.

So the disease is not excess bone signalling in the ordinary sense. It is a receptor misreading a molecule that should mean something else, and Activin A becomes a bone-forming signal only in people carrying the mutation. That makes it an unusually clean target: blocking it should interrupt the pathological process without disturbing normal bone biology.

The trial

In the Phase 3 OPTIMA trial — 63 patients over 56 weeks — the higher dose produced up to a 90% reduction in new heterotopic ossification lesions versus placebo, and both dose levels reduced painful flare-ups.

Sixty-three patients is a substantial fraction of everyone diagnosed with the disease worldwide, which is worth pausing on — recruiting 7% of a global patient population into a single randomised trial is an achievement that depends heavily on organised patient communities.

Reducing flare-ups matters independently of the lesion count. Flares are intensely painful episodes of swelling that precede new bone formation, and patients experience them as the immediate face of the disease.

“For people living with FOP, every irregular new bone formation is a step toward disability and potential loss of mobility,” said OPTIMA investigator Dr Kathryn Dahir.

Why preventing new bone is the only available goal

The therapeutic aim is entirely preventive, and that follows from the disease’s irreversibility. Bone already formed does not go away, and joints already fused stay fused.

A drug reducing new lesions by 90% therefore does not restore anything — it preserves what remains. For a young patient with most of their mobility intact, that is close to everything; for someone already extensively ossified, considerably less.

That logic argues strongly for early treatment, which in turn depends on early diagnosis — historically poor in FOP, where the characteristic malformed big toes present at birth are frequently overlooked and flares are misdiagnosed as tumours, sometimes prompting biopsies that accelerate the disease.

Dosing

Pasatru is given by intravenous injection once monthly, starting at 10 mg/kg with an option to reduce to 3 mg/kg.

The dose-reduction option is a sensible design for a chronic therapy in a young population, allowing exposure to be lowered once disease activity is controlled — relevant when treatment may continue for decades.

The price question

Until now the only approved FOP therapy was Ipsen’s Sohonos (palovarotene), which carries a list price of $624,000. Regeneron has not disclosed Pasatru’s price.

The arithmetic of ultra-rare disease drives those figures. Development costs comparable to any other drug must be recovered across a population of hundreds, and the resulting prices are essentially a function of population size rather than manufacturing cost.

Whether a second entrant produces price competition is an open question. In markets this small, two products can coexist at similar prices without competing meaningfully, since prescribing is driven by clinical fit rather than cost.

How a disease this rare got two drugs

Nine hundred diagnosed patients worldwide would normally be too few to attract any development, and the FOP story shows what changes that.

The causal mutation was identified in 2006, giving the field an unambiguous target and a clear mechanistic hypothesis. That single genetic finding converted a mysterious condition into a tractable drug discovery problem.

Orphan drug incentives did the rest. Market exclusivity, tax credits, waived regulatory fees and the ability to seek approval on small trials change the economics enough that a few hundred patients can support a programme — and the pricing that follows, at hundreds of thousands per year, is the mechanism by which those economics close.

An organised patient community mattered too. Recruiting 63 patients from a population of 900 scattered across the world requires a registry, trusted relationships and families willing to travel — infrastructure that patient organisations in rare disease frequently build themselves, and without which trials in these conditions simply cannot be run.

For a community with almost no options, a second approved therapy sharply curbing the process that steals mobility is a meaningful milestone regardless. Regulatory news, not medical advice.